Cox John

SEC source: 0000899243-20-007240 · doc4.xml · derivative · entry 3

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 10,000 shares

Expires 2023-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is currently exercisable.

SEC source: 0000899243-20-007240 · doc4.xml · nonDerivative · entry 2

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,781

F1 · price: $93.39 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.30 to $93.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-20-007240 · doc4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-005905 · doc4.xml · nonDerivative · entry 2

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,781

F1 · price: $92.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.75 to $92.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-20-005905 · doc4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,136

SEC source: 0000899243-19-013994 · doc4.xml · derivative · entry 2

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,109

Underlying: Common Stock · 2,109 shares

Expires 2029-05-15

F2 · derivative.exercise_date: Award vests in full one year from grant date on May 15, 2020.

SEC source: 0000899243-19-013994 · doc4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,236

F1 · shares: Mr. Cox was awarded 923 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 15, 2020. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001140361-18-024448 · doc1.xml · derivative · entry 2

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,304

Underlying: Common Stock · 3,304 shares

Expires 2028-05-16

F2 · derivative.exercise_date: Award vests in full one year from grant date on May 16, 2019.

SEC source: 0001140361-18-024448 · doc1.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,313

F1 · shares: Mr. Cox was awarded 1,486 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 16, 2019. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001127602-18-010647 · form4.xml · derivative · entry 6

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 193,683 shares

Expires not disclosed

F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

SEC source: 0001127602-18-010647 · form4.xml · derivative · entry 5

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 387,366 shares

Expires not disclosed

F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

SEC source: 0001127602-18-010647 · form4.xml · derivative · entry 4

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,230 shares

Expires not disclosed

F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

SEC source: 0001127602-18-010647 · form4.xml · derivative · entry 3

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,678 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.

F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

SEC source: 0001127602-18-010647 · form4.xml · derivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 136,364 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.

F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

SEC source: 0001127602-18-010647 · form4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Includes 67,780 shares subject to restricted stock units. See also note 4.

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.

SEC source: 0001127602-18-008443 · form4.xml · nonDerivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,094

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-18-008443 · form4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,888

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-18-006418 · form4.xml · derivative · entry 3

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,678

Underlying: Common Stock · 24,339 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018.

SEC source: 0001127602-18-006418 · form4.xml · nonDerivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,861

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-18-006418 · form4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-005561 · form4.xml · derivative · entry 3

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,381 shares

Expires 2018-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the spin-off. These stock options are subject to the terms of the Bioverativ 2017 Omnibus Equity Plan. Under the terms of the Bioverativ 2017 Omnibus Equity Plan, vested stock options are automatically exercised if on the expiration date of such stock option the per share exercise price is less than the closing price of the common stock on that date. Further, under the 2017 Omnibus Equity Plan, after such exercise, the Company will deliver to the reporting person that number of shares subject to the vested stock option less the number of shares with a value that is equal to the aggregate fair market value of (1) the aggregate exercise price of the vested stock option and (2) the amount necessary to satisfy any required withholding of taxes or social insurance contributions.

F2 · derivative.exercise_date: This option is presently exercisable in full.

SEC source: 0001127602-18-005561 · form4.xml · nonDerivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,341

F3 · shares: Represents the number of shares withheld by Bioverativ upon the automatic exercise of stock options to satisfy the aggregate exercise price and required tax withholdings.

SEC source: 0001127602-18-005561 · form4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-18-003801 · form4.xml · derivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,364

Underlying: Common Stock · 136,364 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019.

F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019.

SEC source: 0001140361-17-021758 · doc1.xml · derivative · entry 2

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,434

Underlying: Common Stock · 2,434 shares

Expires 2027-05-18

F2 · derivative.exercise_date: Award vests in full one year from grant date on May 18, 2018.

SEC source: 0001140361-17-021758 · doc1.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,827

F1 · shares: Mr. Cox was awarded 1,206 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 18, 2018. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001127602-17-013535 · form4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,632

F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · derivative · entry 10

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,381

Underlying: Common Stock · 18,381 shares

Expires 2018-02-11

F4 · shares: Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the Spin-Off, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off.

F5 · derivative.exercise_date: This option is presently exercisable in full.

SEC source: 0001127602-17-009673 · form4.xml · derivative · entry 9

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,230

Underlying: Common Stock · 48,230 shares

Expires 2019-02-23

F4 · shares: Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the Spin-Off, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off.

F5 · derivative.exercise_date: This option is presently exercisable in full.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 8

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,048

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 7

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,774

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 6

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,210

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 5

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,851

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 4

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,837

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 3

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,192

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,575

F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units.

SEC source: 0001127602-17-009673 · form4.xml · nonDerivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,979

F1 · shares: Includes restricted stock units granted by Bioverativ Inc. ("Bioverativ") to the reporting person as a result of the conversion of existing Biogen Inc. ("Biogen") cash-settled performance units, market stock units and restricted stock units held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017 ("Spin-off"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards.

F2 · balance_after: Includes 15,300 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off.

SEC source: 0001127602-17-006616 · form4.xml · derivative · entry 3

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 386,675

Underlying: Common Stock · 386,675 shares

Expires 2027-02-14

F4 · derivative.exercise_date: This option vests in full on the third anniversary of the date of grant.

SEC source: 0001127602-17-006616 · form4.xml · derivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,337

Underlying: Common Stock · 193,337 shares

Expires 2027-02-14

F3 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018.

SEC source: 0001127602-17-006616 · form4.xml · derivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,017

Underlying: Common Stock · 73,017 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018.

F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018.

SEC source: 0001127602-17-012948 · form4a.xml · derivative · entry 2

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 387,366

Underlying: Common Stock · 387,366 shares

Expires 2027-02-14

F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.

F3 · derivative.exercise_date: This option vests in full on the third anniversary of the date of grant.

F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.

F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.

SEC source: 0001127602-17-012948 · form4a.xml · derivative · entry 1

Cox John · CIK 0001498428 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,683

Underlying: Common Stock · 193,683 shares

Expires 2027-02-14

F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.

F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018.

F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.

F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing.